Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

Age-dependent Effects of Smoked and Oral Delta-9-THC

Phase 1

Not yet recruiting

Conditions: Abuse, Drug
Intoxication; Cannabinoids
Pain

Interventions: Drug: Smoked Placebo
Drug: Dronabinol
Drug: Cannabis
Drug: Oral Placebo

First Posted Date: 2023-05-18

Last Posted Date: 2024-12-10

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 103

Registration Number: NCT05865470

Dronabinol On the Pain Experience

Phase 4

Suspended

Conditions: Trauma Injury

Interventions: Drug: Standard of care
Drug: Dronabinol

First Posted Date: 2023-04-20

Last Posted Date: 2024-05-23

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 664

Registration Number: NCT05820685

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

The Impact of THC on Pain Modulation in Fibromyalgia

Not Applicable

Recruiting

Conditions: Fibromyalgia, Primary

Interventions: Drug: THC
Drug: Placebo

First Posted Date: 2022-12-09

Last Posted Date: 2024-03-26

Lead Sponsor: Tel Aviv Medical Center

Target Recruit Count: 40

Registration Number: NCT05644054

Locations: 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel

Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks

Phase 2

Not yet recruiting

Conditions: THC

Interventions: Drug: THC
Other: Placebo

First Posted Date: 2022-12-08

Last Posted Date: 2024-08-21

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT05641766

Locations: 🇺🇸
VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Dronabinol for Agitation in Dementia Crossover Trial

Phase 2

Withdrawn

Conditions: Dementia Severe
Behavioral Symptoms
Agitation,Psychomotor
Dementia Moderate

Interventions: Drug: Dronabinol

First Posted Date: 2022-11-10

Last Posted Date: 2024-07-05

Lead Sponsor: Ralph H. Johnson VA Medical Center

Registration Number: NCT05612711

Locations: 🇺🇸
Ralph H. Johnson VA Health Care System, Charleston, South Carolina, United States

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

Phase 2

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2022-08-29

Last Posted Date: 2024-07-03

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT05519111

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

Phase 2

Recruiting

Conditions: Cannabis
THC
HIV
Neuroinflammatory Disease
Neuroinflammatory Response
Microbiome

Interventions: Drug: THC
Drug: CBD

First Posted Date: 2022-08-25

Last Posted Date: 2024-11-14

Lead Sponsor: University of California, San Diego

Target Recruit Count: 90

Registration Number: NCT05514899

Locations: 🇺🇸
HIV Neurobehavioral Research Program (HNRP), San Diego, California, United States

Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)

Phase 1

Recruiting

Conditions: Emergency Service, Hospital
Pharmacokinetics
Malnutrition
Cannabis
Renal Function
Anorexia
Aging

Interventions: Drug: Sativex

First Posted Date: 2022-08-16

Last Posted Date: 2022-09-21

Lead Sponsor: Ove Andersen

Target Recruit Count: 17

Registration Number: NCT05503147

Locations: 🇩🇰
Clinical Research Centre, Hvidovre, Denmark

Behavioral Pharmacology of THC and Beta-Myrcene

Phase 1

Not yet recruiting

Conditions: Cannabis Use

Interventions: Drug: THC
Drug: Beta-Myrcene
Drug: Placebo

First Posted Date: 2022-06-27

Last Posted Date: 2024-12-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 32

Registration Number: NCT05432284

Locations: 🇺🇸
Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Dronabinol After Arthroscopic Surgery

Phase 3

Recruiting

Conditions: Knee Osteoarthritis
Loose Body Knee
Knee Injuries
Meniscus Tear
Synovitis of Knee
Knee Ligament Injury
Chondral Injury of Left Knee
Chondral Injury of Right Knee

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2022-04-19

Last Posted Date: 2024-03-04

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT05335252

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy